Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by 3woodon Jan 14, 2009 4:44pm

561 Views

Post# 15704754

RE: RE: Too Quiet

I appreciate your reply - any idea how long we'll have to wait for $10+. I understand this puts you on the spot but we've all been waiting a long time and are in a very negative position. I don't think many of us doubt the science given the talented team assembled but we doubt DM's word and ability to deliver on his very large promises.

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload